Alliance Pharmaceutical setback for German Oxygent trial
This article was originally published in Clinica
A German ethics committee has rejected Alliance Pharmaceutical's appeal to start a phase 2 clinical trial of its intravascular oxygen carrier, Oxygent, in the prevention of post-op ileus resulting from hypoxia during major surgery.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.